慢性乙型肝炎、肝硬化和肝衰竭患者肠道菌群变化研究*

doi:10.3969/j.issn.1672-5069.2018.06.018

实用肝脏病杂志 ›› 2018, Vol. 21 ›› Issue (6): 899-902.doi: 10.3969/j.issn.1672-5069.2018.06.018

慢性乙型肝炎、肝硬化和肝衰竭患者肠道菌群变化研究^*

郑婷婷, 蒋珊珊, 方钟燎, 陈茂伟

530021南宁市广西医科大学研究生院（郑婷婷,蒋珊珊; 广西病毒性肝炎防治研究重点实验室（方钟燎）; 广西医科大学第一附属医院感染病科（陈茂伟）

收稿日期:2017-08-18 出版日期:2018-11-10 发布日期:2018-12-25
通讯作者: 陈茂伟,E-mail:chenmaowei2008@163.com
作者简介:郑婷婷,女,27岁,硕士研究生。主要从事肝衰竭发病机制和临床研究。E-mail:shifinztt@163.com
基金资助:
*广西病毒性肝炎防治研究重点项目（编号：GKLH20160021）

Changes of intestinal flora in patients with hepatitis B viral infection

Zheng Tingting, Jiang Shanshan, Fang Zhongliao, et al.

College of Graduate,Guangxi Medical University,Nanning 530021,Guangxi Zhuang Autonomous Region

Received:2017-08-18 Online:2018-11-10 Published:2018-12-25

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎（CHB）、肝硬化(LC)和肝衰竭(LF)患者肠道菌群的结构差异。方法纳入CHB患者23例,失代偿期LC患者20例,LF患者6例和成年健康人9例,采用粪便细菌基因组DNA提取试剂盒提取粪便肠道菌群DNA,应用16SrDNA测序技术检测肠道菌群。应用相关生物学软件和统计学软件对测序结果进行分析。结果肠道菌群门分类水平分析显示,每个样本均以拟杆菌门为主,其次为变形菌门;CHB组拟杆菌门丰度（617.83）显著高于LC组（343.16）、LF组（182.15）和健康组（236.66）,差异有统计学意义（P<0.05）;LC组变形菌门丰度（183.16）多于CHB组（35.86）、LF组（18.87）和健康组（53.40,P<0.05）;属分类水平显示,CHB组、LC组和LF组均以拟杆菌属为主,其次为普氏菌属、梭菌属;CHB组普氏菌属丰度（345.28）较LC组（46.75）、LF组（5.63）和健康组（20.14）明显增多,LC组拟杆菌属丰度最少（150.28,P<0.05）。结论 CHB、LC和LF患者肠道菌群结构有显著性差异。拟杆菌为肠道优势菌群,在各样本中菌群丰度发生了变化,了解这些变化可能有助于对疾病发生和处理的认识。

关键词: 乙型肝炎, 肝硬化, 肝衰竭, 肠道菌群

Abstract: Objective To explore the characteristic of intestinal flora changes in patients with chronic hepatitis B （CHB）,liver cirrhosis （LC） and liver failure （LF）. Methods 23 patients with CHB,20 with LC,6 with LF and 9 healthy persons were recruited in this study. The morning excrements in the 58 cases were collected to test the intestinal flora,and the fecal intestinal flora DNA was obtained by fecal bacterial genome DNA extraction kits. The 16SrDNA of metagenomics sequencing technology was applied to analyze the intestinal flora. The biology and SPSS statistical software were applied to analyze the sequencing results to compare the differences of the intestinal flora in patients with CHB,LC and LF. Results In the phylum level of intestinal flora,all samples showed priority to Bacteroidetes,and secondly was Proteobacteria. Bacteroidetesa bundance in patients with CHB （617.83） was much greater than in with LC （343.16） or with LF （182.15） or in healthy persons （236.66,P<0.05）;Proteobacteria in patients with LC（183.16） was much greater than in with CHB （35.86）,with LF（18.87） or in healthy group（53.40,P<0.05）;in the genus,all samples showed the priority to Bacteroides,and secondly were Prevotella and Fusobacterium. Prevotellaa bundance in patients with CHB （345.28） was much greater than in with LC（46.75）,in with LF（5.63） or in healthy group（20.14）;Bacteroides was the least flora in patients with LC（150.28,P<0.05）. Conclusions Bacteroidetes is the dominant bacteria in all samples and the main difference of flora is the abundance in patients with HBV infection. The Proteobacteria is the most flora in patients with CHB,but is the least in patients with LC and Veillonella increases in patients with LF.

Key words: Liver cirrhosis, Hepatitis B, Liver failure, Intestinal flora

郑婷婷, 蒋珊珊, 方钟燎, 陈茂伟. 慢性乙型肝炎、肝硬化和肝衰竭患者肠道菌群变化研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 899-902.

Zheng Tingting, Jiang Shanshan, Fang Zhongliao, et al.. Changes of intestinal flora in patients with hepatitis B viral infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 899-902.

参考文献

[1] 吴迪,宁琴. 2014年慢性病毒性肝炎临床诊疗进展. 实用肝脏病杂志,2015,18(1):10-14.
[2] Seo YS,Shah VH.The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol,2012,18(4):337-346.
[3] Schloss PD,Westcott SL.Introducing mothur:open-source,platform-independent,community-supported software for describing and comparing microbial communities. Appl Environ Microbiol,2009,75(23):7537-7541.
[4] 周永健. 肠道微生态与肝硬化.实用肝脏病杂志,2016,19(2):139-142.
[5] Backhed F,Ley RE,Sonnenburg JL,et al.Host-bacterial mutualism in the human intestine.Science,2005,307(5717):1915-1920.
[6] Qin JJ,Li RQ,Raes J,et al.A human gutmicrobialgenecatalogue established by metagenomic sequencing. Nature,2010,464(7285):59-65.
[7] Han DW.Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol,2002,8(6):961-965.
[8] 梁友方. 肝硬化患者变形杆菌感染与血氨浓度的关系.山西医药杂志,2004,12(33):1022-1023.
[9] Wang T,Cai G,Qiu Y,et al.Structural segregation of gut microbiota between colorectal cancer patient and healthy volunteers. ISME J,2012,6(2):320-329.
[10] Nam YD,Jung MJ,Roh SW,et al.Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing. PLOS One,2011,6(7):e22109.
[11] Tamura M,Tokuda M,Nagaoka S.et al.Isolation and characterization of a bile acid inducible 7alpha-dehydroxylating operon in clostridium hylemonae TN271. Anaerobe,2010,16(2):137-146.
[12] Shah HN,Collins DM. Prevotella H.A new genus to include bacteroides melaninogenicus and related species formerly classified in the genus bacteroides. Int J Syst Bacteriol,1990,40(2):205-208.
[13] Park SK,Kim MS,Roh SW,et al.Blautia stervoris spnov,isolated from human faces. Int J Syst Evol Microbiol,2012,62(4):776-779.
[14] Peng L,Li ZR.Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in caco-2 cell monolayers. J Nutr,2009,139(9):1619-1625.
[15] Lorenzo-Zuniga V,Bartoli R,Planas R,et al.Oral bile acids reduce bacterial overgrowth,bacterialtranslocation,andendotoxemiain cirrhoticrats.Hepatology,2003,37(3):551-557.
[16] Sanchez E,Casafont F,Guerra A,et al.Role of intestinal bacterial overgrowth and intestinal motility inbacterial translocation in experimental cirrhosis.RevEspEnferm Dig,2005,97(11):805-814.
[17] 吴仲文,李兰娟,马伟杭,等. 慢性重型肝炎患者肠道定植抗力变化的研究. 中华肝脏病杂志,2001,9(6):329-330.
[18] Koren O,Spor A.Human oral,gut,and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA,2011,108(Suppl1):4592-4598.
[19] 孙川喻,汤庆娅. 肠道微生态与炎性肠病及益生菌的治疗作用.临床消化病杂志,2014,26(5):312-314.
[20] 陈默,孔银,王君,等. 肠道菌群与非酒精性脂肪肝相关性的研究进展. 中国微生态学杂志,2015,8(27):989-992.

慢性乙型肝炎、肝硬化和肝衰竭患者肠道菌群变化研究^*

Changes of intestinal flora in patients with hepatitis B viral infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[7]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[8]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[9]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[10]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[11]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[12]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[13]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[14]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[15]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.